Monocyte chemoattractant protein-1 (MCP-1) binds to the Duffy antigen (Fy) on erythrocytes, which may act as a sink for several chemokines including MCP-1. We hypothesized that infusion of MCP-1 could result in different pharmacokinetics of MCP and possibly altered pharmacodynamics between Duffy positive and negative individuals. The primary aim of this trial was to compare pharmacokinetics of MCP-1 between Duffy positive and Duffy negative individuals under infusion of recombinant human MCP-1. This was a randomized, double-blinded, placebo-controlled dose escalation trial in 36 healthy volunteers. Subjects received infusions of 0.02-2.0 μg/kg MCP-1 or placebo for one hour. MCP-1 displayed linear pharmacokinetics. Duffy negative individuals reached maximal plasma levels earlier, but plasma concentration profiles were not altered. MCP-1 markedly increased monocyte counts, and estimated EC 50 values were 10-fold higher in Duffy positive than Duffy negative subjects.
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